RESUMO
ABSTRACT: To evaluate the efficacy and safety of plasma rich in growth factors (PRGF) in photorefractive keratectomy (PRK) versus Mitomycin C (MMC).This is a comparative, longitudinal and retrospective case-control study (MMC vs PRGF), in patients with a spherical correction from -0.25 to -8.00 D and cylinder correction from -0.25 to -3.00. The uncorrected distance visual acuity (UDVA), refractive efficacy and safety indices, and changes in endothelial cell density were evaluated. The predictability was assessed with the postoperative manifest spherical equivalent.Forty-four patients (72 eyes) were treated with MMC and twenty-five patients (45 eyes) with PRGF. The final UDVA (LogMar) in MMC was 0.029â±â0.065 and in PRGF it was 0.028â±â0.048 (pâ=â0.383). The efficacy index for MMC was 0.98â±â0.10 and 1.10â±â0.46 for patients treated with PRGF (pâ=â0.062). The safety index for MMC was 1.03â±â0.11 and 1.12â±â0.46 (pâ=â0.158) for PRGF group. The change percentage of endothelial cell density was 0.9â±â11.6 for MMC and 4.3â±â13.1 for PRGF (pâ=â0.593). The predictability for MMC was 92.1% and for the PRGF was 91.9% (pâ=â0.976). Hyperemia, eye pain and superficial keratitis were observed in 11.1% of the MMC group; no adverse events were observed with the PRGF.The use of PRGF in PRK surgery is as effective as MMC. The PRGF shows a better safety profile than MMC for its intraoperative use in PRK.
